1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia
(2025) In Nature Cancer
- Contribution to journal › Article
- 2024
-
Mark
IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation
- Contribution to journal › Article
- 2023
-
Mark
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
- Contribution to journal › Article
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
- Contribution to journal › Article
-
Mark
Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy
- Contribution to journal › Article
- 2021
-
Mark
Clinical and genomic characterization of patients diagnosed with the provisional entity Acute myeloid leukemia with BCR-ABL1, a Swedish population-based study
- Contribution to journal › Article
- 2020
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
- Contribution to journal › Article
-
Mark
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
- Contribution to journal › Article
-
Mark
Cell Surface Markers as Therapeutic Targets in Myeloid Leukemia
(2020) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- Contribution to journal › Article
